Market Newsdesk

Fiverr Announces Expansion into Latin America with Launches in Brazil and Mexico

Following successful entries into markets across Europe, company expands localization efforts to Latin America

NEW YORK–(BUSINESS WIRE)–
Fiverr International Ltd., (NYSE: FVRR), the company that is changing how the world works together, announced that it has expanded its international footprint to Latin America, with launches in both Brazil and Mexico. This follows successful entries Fiverr made into a number of markets in Europe, including Germany, France, Spain, the Netherlands, Italy and Portugal.

“Skilled and talented professionals exist everywhere and providing opportunities for everyone is part of Fiverr’s purpose. Expanding our geographic footprint continues to be a top priority for Fiverr, and we believe there is a great opportunity in the Brazilian and Mexican markets,” said Micha Kaufman, founder and CEO of Fiverr. “By offering users in both countries local payment solutions and the ability to communicate and interact in their native language, not only are we providing a better platform experience, but it will also help drive more efficient buyer acquisition and conversion.”

Fiverr has already seen positive signals in Brazil. With small businesses making up 96% of Brazilian companies, there is a large opportunity to increase brand awareness and subsequently bring new customers to the platform. Fiverr is not only launching in Portuguese but also offering local payment options for buyers in the form of Boleto and Reis. Moreover, localizing the platform for the Brazilian market gives skilled professionals there the ability to take talents that they may have and monetize them, safely, through digital work. In the past year, Fiverr saw a 137% increase in new freelance registrations coming from Brazil.

Mexico is also a country wherein Fiverr has been strong in the past, but sees further opportunity by creating a local language site and offering local payment solutions. In Mexico, buyers will be able to pay with Mexican Peso and a newly established partnership will allow them to pay with cash at Oxxo, Mexico’s leading convenience store chain. This opens an important channel for Fiverr to reach millions of people in a country where many transactions are made in cash. Freelancing is also a growing trend in Mexico – during Q3 2020, Fiverr saw a 109% year-over-year increase in freelancers joining the platform.

About Fiverr

Fiverr’s mission is to change how the world works together. For over 10 years, the Fiverr platform has been at the forefront of the future of work connecting businesses of all sizes with skilled freelancers offering digital services in more than 400 categories, across 8 verticals including graphic design, digital marketing, programming, video and animation. In the twelve months ended September 30, 2020, over 3 million customers bought a wide range of services from freelancers across more than 160 countries. We invite you to become part of the future of work by visiting us at fiverr.com, read our blog and follow us on Facebook, Twitter and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005190/en/

Press Contact

Siobhan Aalders

[email protected]

Holly Steffy

[email protected]

KEYWORDS: Mexico Brazil United States South America Central America North America California New York

INDUSTRY KEYWORDS: Software Internet Public Relations/Investor Relations Data Management Communications Small Business Professional Services Technology

MEDIA:

Logo

Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors

ST. HELIER, Jersey–(BUSINESS WIRE)–
Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting on November 19 through November 21. The presentations include two oral presentations and cover a broad and growing range of topics, with 36 of the 43 presentations prepared by external authors.

The oral presentations on Tumor Treating Fields include:

• Data from EF-19, a post-approval registry study of Tumor Treating Fields in recurrent glioblastoma (GBM), supporting results from Novocure’s EF-11 phase 3 pivotal trial in recurrent GBM and confirming the effectiveness and safety of Tumor Treating Fields as a monotherapy.
• Therapeutic implications of conditional vulnerabilities caused by Tumor Treating Fields exposure in novel combination therapies for non-small cell lung cancer (NSCLC) and brain metastases from NSCLC. Study results suggest that the combination of cisplatin and etoposide together with Tumor Treating Fields may be beneficial for NSCLC patients and patients with brain metastases from NSCLC.

Highlighted topics among poster presentations include the TRIDENT study evaluating Tumor Treating Fields in combination with radiation therapy and temozolomide, long-term survival in GBM patients after Tumor Treating Fields therapy, Tumor Treating Fields in combination with immunotherapy, a subgroup analysis of the EF-14 trial focusing on efficacy of Tumor Treating Fields in elderly patients, optimizing use of Tumor Treating Fields during Covid-19, and safety and quality of life of GBM patients treated with Tumor Treating Fields in China.

“From our first presentation at the SNO Annual Meeting in 2008 to today, we and our external partners have shared nearly 300 presentations on Tumor Treating Fields, strengthening our foundational understanding of our therapy and our science every year,” said Dr. Ely Benaim, Novocure’s Chief Medical Officer. “It remains an honor for us to participate and engage with our scientific colleagues at one of the most important neuro-oncology conferences worldwide. We look forward to gathering virtually to share our work and learn from our partners.”

Oral Presentations

(Abstract #: CBIO-01) Therapeutic implications of conditional vulnerabilities caused by Tumor Treating Fields exposure in novel combination therapies for non-small cell lung cancer and brain metastases from non-small cell lung cancer. N, Karanam, M. Story. (Experimental and Translation Sciences Session I)

(Abstract #: CTNI-77) EF-19: a post-approval registry study of Tumor Treating Fields (TTFields) in recurrent glioblastoma (rGBM). J. Zhu, R. O’Donnell, S. Goldlust, Z. Ram. (Clinical Trials Session I)

Poster Presentations

(Abstract #: CTIM-17) Phase I study of the safety and immunogenicity of personalized neoantigen vaccines and Tumor Treating Fields in patients with newly diagnosed glioblastoma. J. Kodysh, A. Rubinsteyn, A. Blazquez, J. Mandeli, N. Bhardwaj, A. Hormigo. (Clinical trials: Immunologic)

(Abstract #: NIMG-37) Delayed pseudoprogression in two patients undergoing TTFields treatment for newly diagnosed glioblastoma. A. Lowman, S. Hurrell, S. Bobholz, J. Connelly, E. Cochran, W. Mueller, S. McGarry, M. Brehler, P. LaViolette. (Neuro-imaging)

(Abstract #: INNV-10) Effects of TTFields Usage and Duration of Usage on Cellularity and Ki67 Distributions at Autopsy. S. Bobholz, A. Lowman, J. Connelly, E. Cochran, W. Mueller, S. McGarry, M. Brehler, P. LaViolette. (Innovations in patient care)

(Abstract # NCOG-26) Impact of Gender on Tumor Treating Fields Compliance in Patients with Glioblastoma. L. Karpf, S. Chawla, L. Desiderio, S. Mohan. (Outcome measures and neuro-cognitive outcomes)

(Abstract #: CTNI-21) Scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. R. Miller, A. Song, A. Ali, V. Bar-Ad, N. Martinez, J. Glass, D. Andrews, K. Judy, J. Evans, C. Farrell, M. Werner-Wasik, I. Chervoneva, M. Ly, J. Palmer, H. Liu, W. Shi. (Clinical trials: Non-immunologic)

(Abstract #: CTIM-04) Updates for a phase 2 open-labeled study of pembrolizumab plus TTFields plus maintenance temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP). A. Ghiaseddin, S. Warren, A. Allen, D. Sampson, D. Chen, A. Sherman, V. Greene, M. Rahman, D. Tran. (Clinical trials: Immunologic)

(Abstract #: NCOG-52) Tumor Treating Fields in Meningioma. C. Mawrin. (Outcome measures and neuro-cognitive outcomes)

(Abstract #: CTNI-59) First safety analysis of anaplastic meningioma patients treated with Tumor Treating Fields (TTFields). C Mawrin. (Clinical trials: Non-immunologic)

(Abstract #: CTNI-71) TTFields in routine clinical care of newly diagnosed GBM patients in Germany – first report on the fully enrolled TIGER study population. O. Bähr, G. Tabatabai, R. Fietkau, R. Goldbrunner, M. Glas. (Clinical trials: Non-immunologic)

(Abstract #: CTNI-46) A Phase II Trial of Tumor Treating Fields (TTFields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma. M. Harat, M. Blok, M. Adamczak-Sobczak, P. Szymanski, I. Miechowicz, B. Malkowski. (Clinical trials: Non-immunologic)

(Abstract #: CTNI-79) PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. S. Kebir, L. Lazaridis, T. Schmidt, C. Oster, D. Pierscianek, N. Guberina, C. Kleinschnitz, M. Proescholdt, P. Hau, A. Grosu, U. Sure, B. Scheffler, M. Stuschke, M. Glas. (Clinical trials: Non-immunologic)

(Abstract #: RTID-06) Enhancing Tumor Treating Fields therapy for recurrent glioblastoma with targeted and individualized skull remodeling surgery. A multi-center randomized phase 2 trial. N. Mikic, A. Korshoej. (Randomized Trials in Development)

(Abstract #: RTID-12) Phase 2 trial of Tumor Treating Fields (TTFields) plus radiation therapy (RT) plus temozolomide (TMZ) compared to RT plus temozolomide in newly diagnosed glioblastoma (ndGBM). R. Grossman, D. Limon, F. Bokstein, C. Harosh, D. Blumenthal, Z. Ram. (Randomized Trials in Development)

(Abstract #: NIMG-58) The effect of cell confluence on the distribution of Tumor Treating Fields. T. Marciano, S. Levi, Z. Bomzon. (Neuro-imaging)

(Abstract #: NIMG-65) Study of local perturbation in computational modelling on Tumor Treating Fields (TTFields) therapy. O. Zeevi, Z. Bomzon, T. Marciano. (Neuro-imaging)

(Abstract #: INNV-05) Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord. J. De Los Santos, S. Arvatz, O. Zeevi, S. Levi, Z. Bomzon, T. Marciano. (Innovations in patient care)

(Abstract #: CBIO-09) Intratumoral heterogeneity of dielectric properties in glioblastoma. M. Proescholdt, A. Haj, C. Doenitz, N. Schmidt, Z. Bomzon. (Cell biology (cell cycle regulation, DNA repair/modulation))

(Abstract #: RBIO-04) New Therapeutic Delivery Methods for Tumor-Treating Fields for Higher Efficacy. K. Carlson, Z. Bomzon, J. Arle. (Radiobiology)

(Abstract #: COVD-17) Tumor Treating Fields for glioblastoma therapy during the COVID-19 pandemic: Expert consensus on use and experience. N. Gatson, J. Barnholtz-Sloan, J. Drappatz, R. Henriksson, A. Hottinger, P. Hinoul, C. Kruchko, V. Puduvalli, D. Tran, E. Wong, M. Glas. (Innovations in patient care)

(Abstract #: COVD-04) Real-world perspectives: Tumor Treating Fields (TTFields) utility to optimize treatment of patients with glioblastoma (GBM) amidst COVID-19 pandemic. P. Frongillo, M. Shackelford, L. Rain. (Innovations in patient care)

(Abstract #: NCOG-36) First health utilities of glioblastoma patients using TTFields treatment. G. Chavez, C. Proescholdt. (Outcome measures and neuro-cognitive outcomes)

(Abstract #: EXTH-76) The inovivo system: a novel preclinical tool for in vivo delivery of Tumor Treating Fields (TTFields). S. Davidi, R. Blat, A. Shteingauz, Y. Porat, M. Giladi, U. Weinberg, Y. Palti. (Preclinical Experimental Therapeutics)

(Abstract #: EXTH-69) Increased cancer cell permeability following Tumor Treating Fields (TTFields) application in vitro. T. Voloshin, Y. Porat, N. Kaynan, A. Klein-Goldberg, R. Paz, A. Volodin, M. Giladi, U. Weinberg, Y. Palti. (Preclinical Experimental Therapeutics)

(Abstract #: TAMI-04) Tumor Treating Fields (TTFields) hinder glioma cell motility through regulation of microtubule and actin dynamics. T. Voloshin, R. Schneiderman, A. Volodin, R. Shamir, N. Kaynan, E. Zeevi, L. Koren, A. Klein-Goldberg, R. Paz, M. Giladi, Z. Bomzon, U. Weinberg, Y. Palti. (Tumor Microenvironment/Angiogenesis/Metabolism/Invasion)

(Abstract #: EXTH-31) Increasing Tumor Treating Fields (TTFields) efficacy by targeting the G2 cell cycle checkpoint with combined Wee1 or Chk1 inhibitors in glioblastoma cell lines. P. Slangen, M. de Gooijer, M. van Geldorp, O. van Tellingen, G. Borst. (Preclinical Experimental Therapeutics)

(Abstract #: EXTH-33) Valproic acid enhances anti-proliferative effects of Tumor Treating Fields on patient-derived gliosarcoma cells in vitro. S. Michelhaugh, S. Mittal. (Preclinical Experimental Therapeutics)

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2020 and its Quarterly Report on Form 10-Q filed on April 30, 2020, as amended to date, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005188/en/

Investors:

Gabrielle Fernandes

[email protected]

603-206-7047

Media:

Jaclyn Stahl

[email protected]

212-767-7516

 

KEYWORDS: Jersey Europe

INDUSTRY KEYWORDS: Health Oncology Stem Cells Clinical Trials

MEDIA:

Logo

DTS Connected Radio Adds Song Lyrics from LyricFind to its Global Hybrid Radio System

Deep collaboration with LyricFind means DTS Connected Radio users can access the world’s largest, most accurate, multi-language lyrics catalogue for enhanced in-vehicle radio listening

CALABASAS, Calif.–(BUSINESS WIRE)–DTS^®, a global leader in next-generation audio, imaging and sensing technology, and a wholly owned subsidiary of Xperi Holding Corporation (NASDAQ: XPER) (“Xperi”), now offers access, through its DTS Connected Radio, to the most complete, multi-language lyrics catalogue from LyricFind, the world’s leader in licensed lyrics and data solutions.

DTS Connected Radio, built on the largest database of broadcast metadata, is a global hybrid solution that combines over-the-air radio with IP delivered content for a robust, more personalized in-vehicle entertainment experience and is scheduled to launch in a range of 2021 vehicles. LyricFind has 15+ years of licensing history, working directly with music publishers and powers the world’s leading music content platforms.

“We are pleased to be the first and only digital audio solution in our industry to offer this feature globally, which has emerged as a critical automaker requirement. Not only will lyrics further enhance the in-car radio/audio listening experience, but it can also significantly increase engagement,” said Bob Dillon, senior vice president, Connected Radio at Xperi.

“LyricFind’s catalogue is a deep and rich treasure trove for music lovers. It is a significant addition to DTS Connected Radio’s already comprehensive database of premium add-ons such as events, podcasts, and internet radio content that, in combination with its intuitive, personalized metadata capabilities, offers the very best of next generation in-vehicle infotainment,” said Dillon.

The new DTS Connected Radio lyrics feature, which is available in 28 languages, is fully integrated and immediately available to OEMs within the DTS Connected Radio platform. Among the new features are lyrics display and search, synchronized lyrics (for in-cabin sing-along), translation of song lyrics, lyrics for ‘Now Playing’ music on all sources, and more.

“We’re excited to bring our licensed lyrics to Xperi’s many services,” says Roy Hennig, vice president of sales at LyricFind. “Lyrics have the power to boost engagement and amplify entertainment experiences, and we look forward to incorporating lyrics into new innovative spaces and verticals.”

Among the potential benefits of the lyrics integration for OEMs are, first and foremost, adding to the enjoyment of the in-cabin experience for their customers, as well as increased OEM HMI ‘stickiness,’ building of deeper relationships with users, and monetization opportunities.

In addition to DTS Connected Radio, Xperi’s automotive technologies include DTS AutoSense, and HD Radio, all designed to improve the in-vehicle experience, making it safer and more enjoyable. DTS AutoSense comprises occupancy and driver monitoring systems implemented at the edge. HD Radio, which resides in more than 70 million automobiles, is the most successfully deployed commercial digital radio system worldwide.

About Xperi Holding Corporation

Xperi invents, develops, and delivers technologies that enable extraordinary experiences. Xperi technologies, delivered via our brands: DTS, HD Radio, IMAX Enhanced, Invensas, TiVo, and by our startup, Perceive, make entertainment more entertaining, and smart devices smarter. Xperi technologies are integrated into billions of consumer devices, media platforms, and semiconductors worldwide, driving increased value for partners, customers and consumers around the globe.

About LyricFind

LyricFind is the world’s leader in licensed lyrics solutions and is trusted by the top names in the industry, including Amazon, Google, YouTube, Deezer, Soundhound, and iHeartRadio. LyricFind provides its partners with an extensive catalog of accurate and fully legal lyrics, licensed from all the major publishers, as well as 6,000 other publishers and performing rights organizations around the world. LyricFind has also built a premium reporting infrastructure that properly tracks and pays royalties to songwriters and rights holders on a song-by-song and territory-by-territory basis.

XPER-P

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005183/en/

Xperi Media Contact:

Melanie Webber, mWEBB Communications

+ 1 949-307-1723

[email protected]

Xperi Investor Contact:

Geri Weinfeld, Vice President of Investor Relations

+1 818-436-1231

[email protected]

LyridFind Media Contact:

James Paasche, rock paper scissors, inc.

+1 419-973-4229

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Consumer Electronics Mobile Entertainment Publishing Technology Audio/Video Communications TV and Radio Music General Automotive Aftermarket Automotive Software Entertainment Internet Mobile/Wireless

MEDIA:

Posted on November 19, 2020 8:03 am

Cyclo Therapeutics Announces Two Presentations at WORLDSymposium2021

Cyclo Therapeutics Announces Two Presentations at WORLDSymposium2021

Conference Brings Together Medical Researchers and Health Professionals to Exchange Information on Lysosomal Diseases

GAINESVILLE, Fla.–(BUSINESS WIRE)–
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol^® Cyclo™) in the treatment of Niemann-Pick Disease Type C (NPC) today announced that the company will present on its clinical and drug development program for the orphan drug, Trappsol^® Cyclo™, at the 17th Annual WORLDSymposium2021, a leading medical and scientific conference for professionals working to advance understanding and treatments for lysosomal storage diseases, including NPC. Cyclo Therapeutics’ proposals to present at the conference were accepted after scientific and medical review. The conference will be held virtually between February 8–12, 2021.

Cyclo Therapeutics will make both a platform presentation (pre-taped with opportunity for live Q and A with the audience) and a poster presentation (with availability for discussion at a prescribed time) with data from two clinical trials. Exact timing for each presentation has not yet been determined by the organizers. Updates on timing of each presentation will be posted to the Cyclo Therapeutics website.

Caroline Hastings, MD, UCSF Benioff Children’s Hospital Oakland, California, Principal Investigator, will present data on safety and mechanism of action from the completed Phase I clinical trial using the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol^® Cyclo™, administered intravenously, in patients 18 years and older. Dr. Hastings, a member of the Company’s Scientific Advisory Board, is also the first physician in the United States to use this class of drug and specifically Cyclo Therapeutics’ product on a compassionate use basis in NPC patients. Her work paved the way for the present drug development program at Cyclo Therapeutics in NPC.

Julian Raiman, MD, Birmingham Women’s and Children’s Hospital, United Kingdom, Principal Investigator, will present interim data on safety and efficacy from the Phase I/II trial underway in the UK, Sweden and Israel using Trappsol^® Cyclo™ in NPC patients aged 2 and older.

Sharon Hrynkow, PhD, the company’s Scientific Officer and Senior Vice President for Medical Affairs, is a co-author of both presentations.

Presentation Details:

Poster presentation: “Update on Phase I study to evaluate the single- and multiple-dose pharmacokinetics of intravenous Trappsol^® Cyclo™ (HPβCD) in patients with Niemann-Pick disease type C (NPC-1) and the effects of dosing upon biomarkers of NPC disease. Caroline Hastings, MD; Benny Liu, MD (Alameda Health System and UCSF Benioff Children’s Hospital), Alan Boyd, MD (Boyd Consultants, UK) and Sharon Hrynkow PhD.

Platform presentation and Poster presentation: Update on Safety and Efficacy Results for Phase I/II trial of Hydroxypropyl Beta cyclodextrin (HPβCD) Administered Intravenously in Patients with Niemann-Pick type C1 Disease.

Julian Raiman, MD; Reena Sharma, MD (European Coordinating Investigator and Principal Investigator, Salford Royal Foundation Trust Hospital, Salford, UK); Martin Paucar, MD (Principal Investigator, Karolinska Institute, Stockholm, Sweden); Orna Staretz-Chacham MD (Principal Investigator, Soroka Medical Center, BeerSheva, Israel); Ronen Spiegel, MD (Principal Investigator, Emek Medical Center, Afula, Israel); Alan Boyd, MD; Caroline Hastings, MD; and Sharon Hrynkow, PhD.

About Cyclo Therapeutics:

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company’s Trappsol^® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol^® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol^® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com.

Safe Harbor Statement:

This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005165/en/

Investor/Media Contact:

Jeffrey L. Tate, Ph.D., COO

Cyclo Therapeutics, Inc.

[email protected]

+1 (386) 418-8060

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Other Health Research Managed Care General Health Pharmaceutical Mental Health Hospitals Clinical Trials Science Biotechnology Other Science Health

MEDIA:

Posted on November 19, 2020 8:03 am

Field Roast’s Chao Creamery More than Doubles Walmart Distribution

Field Roast’s Chao Creamery More than Doubles Walmart Distribution

Leading plant-based cheese varieties now available at more than 18,000 retail locations nationwide, including Walmart, Meijer, HEB, Safeway and Ahold

CHICAGO–(BUSINESS WIRE)–
Greenleaf Foods, SPC, owner of Field Roast Grain Meat Co™ (“Field Roast”), announced today that its portfolio of Chao Creamery dairy-free cheeses is now available at over 18,000 retail locations nationwide. Following this fall’s launch of five new Chao Creamery flavors and forms, Walmart more than doubled its distribution of the product line to more than 2,000 store locations and added the new Creamy Original Shreds and Mexican Style Blend Shreds.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005424/en/

Field Roast’s Chao Creamery cheese varieties are now available at more than 18,000 retail locations nationwide, including Walmart, Meijer, HEB, Safeway and Ahold. (Photo: Business Wire)

“Chao Creamery has grown 35% year over year and is significantly outpacing others in the category,” said Dan Curtin, president of Greenleaf Foods. “It’s been rewarding to see how Chao lovers are experimenting with our new products in the kitchen, and I’m excited to make these products even more accessible for new and existing fans alike.”

For three consecutive years, Chao Creamery Creamy Original Slices have held the #1 spot for plant-based cheese slice variety in U.S. retail with a dollar sales volume landing 39% higher than the second most popular plant-based cheese slice option, and for a great reason.¹ The dairy-free cheese slices’ unique flavor profile comes from its coconut-based ingredients and special fermented tofu ingredient, which combine to provide an unmatched buttery, umami bite.

With the growing distribution of Chao Creamery’s product line across produce and dairy aisles nationwide, consumers will have the opportunity to use the products they love for various occasions this holiday season, from a photo-worthy dairy-free cheese board featuring the newest Chao Blocks to a crowd-pleasing salad topped with Mexican Style Shreds.

In October, Field Roast first announced its Chao Creamery line extension and the debut of new flavors along with new forms of blocks and shreds. As consumer demand for the product grew, the new Chao products quickly found additional distribution in key retailers in the US. Through the end of this year, the Chao Creamery portfolio will begin to appear in either the produce aisle or the dairy aisle of new store locations, including Walmart, HEB, Meijer, Safeway and Ahold.

Field Roast believes the best dishes have yet to be discovered. Its portfolio of high-quality plant-based burgers, sausages, roasts, appetizers and entrees, in addition to its leading Chao Creamery dairy-free cheese products, are crafted for those who want to discover, indulge and share in bold taste experiences.

For more information on Field Roast, visit fieldroast.com and follow @FieldRoast on Facebook, Instagram and YouTube.

About Greenleaf Foods, SPC

Greenleaf Foods, SPC, is transforming plant-based protein with a wide array of delicious and innovative products that satisfy consumers interested in adding protein variety to their diets. Our leading brands include Lightlife® (“Lightlife”) and Field Roast Grain Meat Co.™ (“Field Roast”). Together, these brands are delighting loyal, longtime fans and enticing new ones who never knew plant-based protein could taste so good. The Lightlife and Field Roast portfolios feature nearly 50 products and represent a leading market position in the refrigerated, plant-based protein category in the U.S. Greenleaf Foods, SPC is a wholly owned, independent subsidiary of Maple Leaf Foods Inc. (TSX:MFI).

¹ SATORI, SPINS, Total MULO + Natural Channel, Latest 52 Weeks Ending 10/4/20.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005424/en/

Nicole Pierce, Edible, [email protected]

KEYWORDS: United States North America Canada Illinois

INDUSTRY KEYWORDS: Retail Supermarket Food/Beverage

MEDIA:

Logo

Photo

Field Roast’s Chao Creamery cheese varieties are now available at more than 18,000 retail locations nationwide, including Walmart, Meijer, HEB, Safeway and Ahold. (Photo: Business Wire)

RingCentral Adds Key Security and Privacy ISO Certifications to Cloud Communications Platform

Certifications reaffirm the company’s commitment to ensuring secure and private business communications

BELMONT, Calif.–(BUSINESS WIRE)–RingCentral, Inc. (NYSE: RNG) a leading provider of global enterprise cloud communications, collaboration, and contact center solutions, today announced that RingCentral Office®, the company’s flagship unified communications solution that includes video, team messaging, and a cloud phone system has achieved three internationally recognized ISO certifications including ISO 27001, ISO 27017, and ISO 27018 for information security best practices.

With these third-party certifications in place, RingCentral meets a stringent set of requirements around security and privacy. These certifications test the maturity of RingCentral’s processes and programs against the highest international standards and demonstrate RingCentral’s ongoing commitment to ensure customers’ security and privacy.

“When your people are working from anywhere, providing secure and private cloud-based business communications are essential,” said Michael Machado, Chief Security Officer at RingCentral. “We are focused on ensuring our customers can run their business on a reliable, trusted, and secure communications platform. Adding internationally recognized ISO certifications for information security and privacy best practices demonstrates our ongoing commitment to protecting our customers.”

The three ISO certifications include:

• ISO 27001: This certification recognizes that RingCentral has designed and implemented a set of controls and measures to effectively manage risk and achieve compliance on a continual basis to protect customer information and data. The certification also demonstrates that RingCentral has a robust security program with rigorous management activity and technical controls to address leading Confidentiality, Integrity, and Availability (CIA) principles of Information Security.
• ISO 27017: Provides guidelines for information security controls applicable to and specific to the provisioning and use of cloud services. RingCentral’s ISO/IEC 27017 certification demonstrates that the company extends its disciplined Information Security Management System (ISMS) to the operation of its cloud services.
• ISO 27018: Establishes commonly accepted controls and guidelines for implementing measures to protect Personally Identifiable Information (PII) for the public cloud computing environment. The ISO/IEC 27018 certification demonstrates RingCentral’s commitment to the privacy of its customers’ data. It further demonstrates that RingCentral, acting as a processor of its customers’ PII data, has implemented controls for protecting PII.

“Security and compliance are crucial parts of business communications as companies deploy solutions that enable their employees to work from anywhere and on any device,” said Wayne Kurtzman, Research Director of Communities and Collaboration at IDC. “ISO certifications are frequently demanded by the enterprise and underscore a company’s commitment to meeting those demands.”

For more information about RingCentral’s ISO certifications, click here.

About RingCentral

RingCentral, Inc. (NYSE: RNG) is a leading provider of cloud Message Video Phone™ (MVP™), customer engagement, and contact center solutions for businesses worldwide. More flexible and cost-effective than legacy on-premise PBX and video conferencing systems that it replaces, RingCentral empowers modern mobile and distributed workforces to communicate, collaborate, and connect via any mode, any device, and any location. RingCentral’s open platform integrates with leading third-party business applications and enables customers to easily customize business workflows. RingCentral is headquartered in Belmont, California, and has offices around the world.

©2020 RingCentral, Inc. All rights reserved. RingCentral, RingCentral Office, Message Video Phone, MVP, and the RingCentral logo are trademarks of RingCentral, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005294/en/

Lela Gradman

[email protected]

+1-650-525-6264

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Technology Mobile/Wireless Software Networks Internet

MEDIA:

Logo

Desktop Metal Begins Global Shipments of Shop System for Mid-Volume Metal 3D Printing Manufacturing

• Desktop Metal’s binder jetting system, designed to enable affordable, batch production of high-quality metal parts, is now being installed throughout North America, EMEA and APAC.
• The announcement follows Desktop Metal’s recent signing of a definitive business combination agreement with Trine Acquisition Corp. (NYSE: TRNE) to accelerate its go-to-market efforts and drive advanced R&D.

BOSTON–(BUSINESS WIRE)–
Desktop Metal​, a leader in mass production and turnkey additive manufacturing solutions, today announced the Shop System™, the world’s first metal binder jetting system designed for machine shops, is being manufactured in volume and shipped to customers around the world. With installations underway throughout North America, EMEA and APAC, manufacturers such as Jade Creaction LDA in Portugal, Wall Colmonoy Limited in the UK, Alpha Precision Group in the USA, E.A.C. in France, and Hong Kong Productivity Council (HKPC) in Hong Kong, are leveraging high-quality binder jetting technology to print end-use metal parts in volume and at part costs unattainable with legacy additive manufacturing processes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005274/en/

The announcement follows Desktop Metal’s recent signing of a definitive business combination agreement with Trine Acquisition Corp. (NYSE: TRNE), to accelerate its go-to-market efforts and further drive its relentless efforts in advanced R&D.

First unveiled last November at the 2019 Formnext trade conference in Frankfurt, Germany, the Shop System is designed to bring metal additive manufacturing to machine and job shops with an affordable, turnkey solution that achieves exceptional surface finish parts with rich feature detail at speeds up to 10 times those of legacy powder bed fusion additive manufacturing (AM) technologies. With the Shop System, users can now print end-use metal parts for use in a variety of industries spanning from automotive and oil & gas to consumer products and electronics.

“The Shop System offers the most cost-effective, highest resolution mid-volume production solutions in the industry. Its high-speed, single-pass print engine introduces high-quality binder jetting to an entirely new market of machine shops, casting foundries, and powder metal component suppliers,” said Ric Fulop, CEO and co-founder of Desktop Metal. “With the Shop System, engineers and plant operators can now eliminate many of the constraints previously imposed by traditional manufacturing methods, like CNC machining, and achieve affordable, reliable, and flexible batch production of complex parts.”

Many early adopters of the technology are already realizing the potential for expanding their manufacturing efforts.

• Jade Creaction LDA is a leading European company specializing in luxury leather goods, jewelry and watches for several French, Italian and American luxury brands. “Our luxury fashion clients are renowned global brands in the industry, and the Desktop Metal Shop System will allow us to quickly respond to their needs with faster production solutions,” said Christophe Pereira, CEO of Jade. “3D printing allows us freedom from multi-stage manufacturing tooling combined with technology innovation that gives our clients’ designers unlimited creative power.”
• AFPMA de l’Ain of France is the training center of the UIMM (French metallurgical industries association) of Ain French region, with the mission to provide skills that meet the needs of industrial companies in the Ain region, through initial and continuous training. “AFPMA has invested in metal additive manufacturing technologies from Desktop Metal in order to deliver the best technical training in AM,” said Patrice Mayoral, AFPMA CEO. “The Shop System and the Studio System are two complementary machines that will allow us to train operators and realize demonstrators to show trainees, thanks to real applications, the possibilities of each machine and technology to understand the impact of the design and process parameters on the global value chain. Being among the first adopters allows us to be part of European and French national working groups in order to develop qualification and certification for additive manufacturing and validate the training processes to be aligned with the industry needs.”
• E.A.C., based in France, started its development in 2002 with Swimwear and Lingerie markets. The company is now more focused on the Luxury markets such as leather, cosmetics, packaging, wines & spirits, and jewelry with worldwide clientele. “By enabling mass production of amazingly intricate geometries, metal binder jetting is about to transform the luxury goods space,” said Patrick Chouvet, Manager E.A.C. “As a pioneer in the use of additive manufacturing in luxury goods for some of the world’s most valuable and iconic brands, E.A.C. has been exploring metal Binder Jetting technology over the past four years. After a comprehensive review and benchmarking of the competitive landscape, we chose the Shop System for its unparalleled print quality, throughput, and affordability.”
• Cosmind, based in Italy, is a technologically-advanced company with experience and know-how in the fields of sheet metal processing, metallic carpentry, high precision mechanical processing, sheet metal forming and assembly. “Cosmind is highly focused on technological innovations. Throughout the years, we have constantly introduced the latest production technologies,” said Carmine Donisi, CEO of Cosmind. “We strongly believe that Blinder Jetting technology is the natural evolution of the manufacturing sector. In Desktop Metal, we have found all the characteristics of quality and innovation that will certainly allow us to diversify our production.”
• Alpha Precision Group, (APG) based in Pennsylvania, is a leading provider of engineered powder metal, metal injection molding (MIM), and machined components with a primary focus on providing products that are consistent with reducing emissions, improving fuel economy, and enhancing engine performance. “APG is extremely excited about the recent purchase of the Shop System as we know that this technology is going to change the way that engineers think, not just from a manufacturing perspective but from a limitless design perspective,” said Phillip McDonald, Advanced Manufacturing Engineer at APG. “This technology enables our customers to iterate designs extremely quickly and prototype products with no tooling costs, all with incredibly short lead times. The future is here.”
• Impac Systems Engineering (ISE), a Texas-based professional engineering services firm, has utilized technology, process and people to solve customer engineering challenges. “For our customers, Impac is a trusted partner, providing a broad suite of engineering and manufacturing solutions across the entire product life cycle,” said Scot Andrews, President of Impac Systems Engineering. “Our 3D printing services play a key role in helping our customers get to market quicker, with better products. With the Shop System, we can scale to hundreds of near-net-shape parts daily — with dramatically reduced labor costs and expanded geometric flexibility relative to traditional methods such as machining and casting.”
• VTT Technical Research Center, based in Finland, VTT is a visionary research, development and innovation organization that drives sustainable growth and tackles the biggest global challenges of our time, turning them into opportunities for business growth. “We are excited to work with this new metal Binder Jetting technology that has matured from lab to production,” said Pasi Puukko, Research Team Leader, Advanced Manufacturing at VTT. “We’ll first focus on applications benefitting from this technology, but on the longer run, we are certainly looking also for new material solutions, widening the range of metal AM materials and therefore, better serving our customers’ needs.”
• CETIM, the Technical Centre for Mechanical Engineering Industry, is the leading French leader in the fields of mechanical engineering innovation and R&D, and one of the French leaders on metal additive manufacturing development. “3D printing allows CETIM to design parts with new properties and functionalization like thermal behavior, lightening, customization, electrical performances or tribology optimization,” said Pierre Chalandon, Chief Operations Officer for materials, processes and industrialization at CETIM. “Metal binder jetting technology is opening new opportunities — no tooling process, increasing production capacities, decreasing the global cost, and allowing new materials. Desktop Metal technologies, including the new Shop System, completes our additive manufacturing machines park. We chose to be one the first Shop System adopters, because we are convinced it is now possible for metal binder jetting to decrease the global cost, increase the production rate, increase the quality and definition and accuracy, develop new materials and simulate the process — especially sintering — to control the capability and the quality.”

Delivering High-quality Binder Jetting to the Machine Shop Market

The Shop System offers reliable production of serial batches of complex, end-use metal parts in a fraction of the time and cost of conventional manufacturing and comparably priced AM technologies. Featuring the highest resolution and most advanced print engine in the binder jetting market, the Shop System is a complete end-to-end solution that includes a single pass, binder jetting printer; a drying oven for hardening green parts prior to depowdering; a powder station for depowdering parts with built-in powder recycling; Desktop Metal’s furnace designed for accessible, industrial-strength sintering; and integrated powder handling accessories and workflow. This turnkey solution together seamlessly integrates with existing shop operations.

Key Shop System benefits include:

• Easy to use and operate. Designed with the modern machine shop in mind, the Shop System produces parts with excellent surface finish and resolution at the push of a button through its easy-to-use software interface. It features engineered powders and processing parameters optimized for use with the system to deliver exceptional quality and ensure repeatability.
• High productivity. Featuring a high-speed, single pass print carriage, the Shop System produces high-quality, complex metal parts up to 10 times the speed and at a fraction of the cost of legacy PBF additive manufacturing technologies, amplifying customers’ existing output with up to hundreds of end-use metal parts per day. Speeds up to 800 cc/hour enable batches of tens or hundreds of complex printed parts in as little as five hours.
• Superior print quality. Customers can print dense, complex parts with incredibly fine feature detail.
• Rich feature detail with exceptional surface finish. Achieved through an advanced single pass printhead with 1600 native DPI, the Shop System delivers 400% higher resolution than legacy binder jetting systems. Reliable print quality is supported by the printhead’s 5x nozzle redundancy — 25 percent higher redundancy than comparable binder jetting systems.

Binder Jetting Technology Ushers in Additive Manufacturing 2.0

As a solution for mid-volume parts production through AM, the Shop System is a critical element of the Additive Manufacturing 2.0 revolution that is reshaping the future of manufacturing. As the emergence of AM 2.0 enables throughput, repeatability, and part costs that can compete with conventional manufacturing processes, the additive manufacturing sector is expected to surge from $12 billion in 2019 to an estimated value of $146 billion by the end of the decade¹.

“Many of the benefits that have long been touted for 3D printing – mass customization, complex geometries, lightweighting, assembly consolidation, tool-free manufacturing, digital inventories, and more – all come bundled as part of AM 2.0,” said Fulop. “Taken together, this suite of benefits represents a new approach to the way metal parts are being designed, prototyped and now, with the Shop System, manufactured.”

With variable build box configurations ranging from 4L to 16L, the Shop System is designed to scale throughput to each shop’s needs. Pricing starts at $166,500 for the 4L printer (350 x 220 x 50mm) and up to $241,500 for the 16L printer (350 x 220 x 200mm). In addition with the Shop System’s end-to-end hardware solution, customers will gain access to Desktop Metal’s Fabricate MFG™ build preparation software, as well as to the Company’s newly-released Live Sinter™ application, a sintering process simulation software that corrects for shrinkage and distortion of binder jet 3D printed parts during sintering, minimizing process trial and error while improving accuracy.

The general availability of the Shop System is another major announcement that follows Desktop Metal’s recent signing of a definitive business combination agreement with Trine Acquisition Corp. (NYSE: TRNE), a special purpose acquisition company led by Leo Hindery, Jr., and HPS Investment Partners, a global credit investment firm with over $60 billion in assets under management.

About Trine Acquisition Corp

Trine Acquisition Corp is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. For more information, visit www.trineacquisitioncorp.com.

About Desktop Metal

Desktop Metal, Inc., based in Burlington, Massachusetts, is accelerating the transformation of manufacturing with end-to-end 3D printing solutions. Founded in 2015 by leaders in advanced manufacturing, metallurgy, and robotics, the company is addressing the unmet challenges of speed, cost, and quality to make 3D printing an essential tool for engineers and manufacturers around the world. Desktop Metal was selected as one of the world’s 30 most promising Technology Pioneers by the World Economic Forum; named to MIT Technology Review’s list of 50 Smartest Companies; and recognized among the most important innovations in engineering in Popular Science’s “Best of What’s New.” For more information, visit www.desktopmetal.com​.

1. Based on Wohlers Report 2020, Wohlers Associates

Forward-Looking Statements Legend

This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Desktop Metal, Inc. (“Desktop”) and Trine Acquisition Corp. (“Trine”), including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the services offered by Desktop and the markets in which it operates, and Desktop’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Trine’s securities, (ii) the risk that the transaction may not be completed by Trine’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Trine, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the shareholders of Trine and Desktop, the satisfaction of the minimum trust account amount following redemptions by Trine’s public shareholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger, (vi) the effect of the announcement or pendency of the transaction on Desktop’s business relationships, performance, and business generally, (vii) risks that the proposed transaction disrupts current plans of Desktop and potential difficulties in Desktop employee retention as a result of the proposed transaction, (viii) the outcome of any legal proceedings that may be instituted against Desktop or against Trine related to the agreement and plan of merger or the proposed transaction, (ix) the ability to maintain the listing of Trine’s securities on the New York Stock Exchange, (x) the price of Trine’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Desktop plans to operate, variations in performance across competitors, changes in laws and regulations affecting Desktop’s business and changes in the combined capital structure, (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, and (xii) the risk of downturns in the highly competitive additive manufacturing industry. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Trine’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, the registration statement on Form S-4 and proxy statement/consent solicitation statement/prospectus discussed below and other documents filed by Trine from time to time with the U.S. Securities and Exchange Commission (the “SEC”). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop and Trine assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Desktop nor Trine gives any assurance that either Desktop or Trine will achieve its expectations.

Additional Information and Where to Find It

This document relates to a proposed transaction between Desktop and Trine. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed transaction, Trine filed a registration statement on Form S-4 with the SEC on September 15, 2020, which included a proxy statement of Trine, a consent solicitation statement of Desktop and a prospectus of Trine. Trine also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of Trine are urged to read the registration statement, the proxy statement/consent solicitation statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders may obtain free copies of the proxy statement/consent solicitation statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Trine through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by Trine may be obtained free of charge from Trine’s website at www.trineacquisitioncorp.com or by written request to Trine at Trine Acquisition Corp., 405 Lexington Avenue, 48th Floor, New York, NY 10174.

Participants in Solicitation

Trine and Desktop and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Trine’s stockholders in connection with the proposed transaction. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/consent solicitation statement/prospectus regarding the proposed transaction. You may obtain a free copy of these documents as described in the preceding paragraph.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005274/en/

For Trine Acquisition Corp.

Pierre Henry

[email protected]

For Desktop Metal

Lynda McKinney

[email protected]

Investor Relations

Mike Callahan / Tom Cook

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Software Finance Steel Engineering Professional Services Technology Manufacturing Other Technology

MEDIA:

Photo

The Desktop Metal Shop System™, the world’s first metal binder jetting system designed for machine shops, is being manufactured in volume and shipped to customers around the world. (Photo: Business Wire)

Photo

This delicate and complex jewelry ornament, designed by luxury goods manufacturer E.A.C. of France, was 3D printed on the Shop System in steel, and subsequently gold-plated. This one-of-a-kind piece could not be produced any other way. (Photo: Business Wire)

This Holiday Season, Warm Your Hearts and Your Engines at Advance Auto Parts

Advance your holiday with automotive essentials, stocking stuffers and more

RALEIGH, N.C.–(BUSINESS WIRE)–
Whether you’re treating your car, searching for stocking stuffers or preparing your family’s four-wheeled sleigh for a road trip this holiday season, Advance Auto Parts (NYSE: AAP), a leading automotive aftermarket parts retailer, has you covered.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005161/en/

• Treating your car? A DieHard^® battery (starting at $119.99, available at Advance and Carquest), wash and wax essentials from top brands and WeatherTech floor mats (starting at $59.99) will keep your ride looking fresh and running strong.
• For stocking stuffers, you can’t go wrong with Advance gift cards, which can be purchased and redeemed online or in store. Other ideas include household batteries, Hot Wheels toy cars and wrench sets.
• To get road trip ready, Advance is your stop. From Sylvania® headlight bulbs (starting at $10.99) and Slime® flat tire repair kits ($34.99, reg. $44.99), to wireless-charging phone mounts ($34.99, reg. $39.99) and even a French fry holder ($9.99), Advance has what you need to hit the road in comfort and confidence.

Doors open at 7:30 a.m. on Black Friday and free curbside pickup is available for most in-stock products. For online shoppers, the same great deals are available at AdvanceAutoParts.com on Cyber Monday and throughout the season.

“It’s no secret that holiday shopping looks different this year, but our promise to motorists is a safe, convenient experience with Team Members who are eager to help with care and speed,” said Jason McDonell, Chief Marketing Officer. “Whether you’re getting your car winter ready with a new DieHard battery or searching for the perfect gift for the motorist in your life, Advance has what you need.”

Save even more at Advance this holiday season by signing up for Speed Perks. Members earn bonus points on all in-store and online purchases. Speed Perks members are also the first to hear about seasonal promotions and other special deals.

All items listed above are also available at participating Carquest locations.

About Advance Auto Parts

Advance Auto Parts, Inc. is a leading automotive aftermarket parts provider that serves both professional installer and do-it-yourself customers. As of October 3, 2020, Advance operated 4,811 stores and 168 Worldpac branches in the United States, Canada, Puerto Rico and the U.S. Virgin Islands. The Company also serves 1,269 independently owned Carquest branded stores across these locations in addition to Mexico and various Caribbean islands. Additional information about Advance, including employment opportunities, customer services, and online shopping for parts, accessories and other offerings can be found at www.AdvanceAutoParts.com.

Sylvania^® and Slime^® are trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005161/en/

Investor Relations:

Elisabeth Eisleben

T: (919) 227-5466

E: [email protected]

Media Relations:

Darryl Carr

T: (984) 389-7207

E: [email protected]

KEYWORDS: United States North America West Virginia Virginia North Carolina New York Florida District of Columbia

INDUSTRY KEYWORDS: Automotive Manufacturing Aftermarket Other Retail Automotive Online Retail Manufacturing Specialty Other Automotive General Automotive Retail Performance & Special Interest

MEDIA:

Logo

Photo

Advance Auto Parts open at 7:30 a.m. on Black Friday and free curbside pickup is available for most in-stock products. (Photo: Business Wire)

Tablo Hemodialysis Systems Deployed to Guam Hospitals by U.S. Department of Health and Human Services for Emergency Response

Guam to receive HHS emergency deployment of Outset Medical’s mobile, easy-to-use dialysis technology for patients with kidney failure.

SAN JOSE, Calif.–(BUSINESS WIRE)–
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced along with the U.S. Department of Health and Human Services (HHS), the deployment of 15 Tablo Hemodialysis Systems to hospitals in Guam that are experiencing a surge in need for acute hemodialysis due to COVID-19. Outset’s clinical team and field support staff will accompany the Tablo devices to provide training and support to the Guamanian clinicians treating acute kidney injury and end stage renal disease (ESRD) patients who have been hospitalized.

This is the second time HHS has sent Tablo systems to emergency locations since signing a multiyear contract with Outset Medical in October 2019. The agency’s stated mission for Tablo’s unique, all-in-one technology is to serve dialysis patients in communities hit by natural disasters. Tablo was first deployed to help New York City hospitals solve shortages in equipment and dialysis fluids during the pandemic’s initial peak in the spring.

“Tablo’s ease of use enables health care professionals, even those previously untrained in dialysis, to learn how to operate the system safely in just a few hours, and provide dialysis urgently to patients in critical need,” said Outset Medical Chief Executive Officer Leslie Trigg. “Tablo’s unique features like real-time remote patient monitoring and integrated water purification on demand have proven especially helpful in providing flexibility to our provider partners when managing dialysis in the ICU.”

“The varied ways that our partners, including many leading national and regional Integrated Delivery Networks (IDNs), have leveraged Tablo to optimize care for their patients demonstrates Tablo’s versatility as an enterprise solution for acute and chronic dialysis — increasing flexibility and reducing cost from the ICU to home. With our growing home dialysis program, we hope to give more patients and their families access to an easier option to safely and effectively dialyze from the comfort of home,” Trigg added.

About the Tablo Hemodialysis System

Tablo is an FDA-cleared enterprise solution for dialysis, designed and produced in Silicon Valley specifically to reduce the cost and complexity of dialysis across all care settings. Requiring only an electrical outlet and tap water to operate, the mobile Tablo system frees patients and providers from the burdensome infrastructure required to operate conventional dialysis machines. The machine’s integrated functionality enables it to serve as a dialysis clinic on wheels and enables providers to standardize to a single platform that can be used across a wide spectrum of care settings. Wireless data, sensor-based automation and an animated touchscreen make the system easy to learn and use. Leading health systems and medical centers across the U.S. have adopted Tablo for hospital and clinic dialysis, and the U.S. Department of Health and Human Services (HHS) awarded a contract for the use of Tablo in communities hit by natural disasters in October of 2019.

About Outset Medical

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005478/en/

Investor Contact

Lynn Lewis or Brian Johnston

Gilmartin Group

[email protected]

KEYWORDS: Guam Australia/Oceania United States Asia Pacific California

INDUSTRY KEYWORDS: Software Managed Care Networks General Health Data Management White House/Federal Government Medical Devices Technology Hospitals Nursing Health Public Policy/Government

MEDIA:

Logo

Cresco Labs Announces Upcoming Conference Participation

CHICAGO–(BUSINESS WIRE)–
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following conferences:

• Cowen’s 2020 Boston Cannabis Conference – November 30^th, 2020 – Management will participate in virtual one-on-one meetings. Charlie Bachtell, CEO and Co-Founder, will participate on the “U.S. MSOs: The Mid-West” panel. Barrington Rutherford, SVP of Real Estate & Community Integration, will participate on the “inclusion & Diversity” panel.
• Roth Virtual Deer Valley Consumer Event – December 9^th-11^th, 2020 – Management will participate in virtual one-on-one meetings and Charlie Bachtell, CEO and Co-Founder, will participate on a panel.
• 2020 Cantor Fitzgerald Virtual Cannabis MSO Summit – December 15^th-16^th, 2020 – Charlie Bachtell, CEO and Co-Founder, will participate in a fireside chat. Register here.

About Cresco Labs

Cresco Labs is one of the largest vertically-integrated multi-state cannabis operators in the United States. Cresco is built to become the most important company in the cannabis industry by combining the most strategic geographic footprint with one of the leading distribution platforms in North America. Employing a consumer-packaged goods (“CPG”) approach to cannabis, Cresco’s house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco, Remedi, High Supply, Reserve, Good News and Mindy’s Chef Led Artisanal Edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside, Cresco’s national dispensary brand, is a wellness-focused retailer designed to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco provides the industry’s first national comprehensive Social Equity and Educational Development (SEED) program designed to ensure that all members of society have the skills, knowledge and opportunity to work in and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Forward Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the company’s CSE Listing Statement filed with SEDAR; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco’s shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005467/en/

Media:

Jason Erkes, Cresco Labs

Chief Communications Officer

[email protected]

Investors:

Jake Graves, Cresco Labs

Senior Analyst, Investor Relations

[email protected]

For general Cresco Labs inquiries:

312-929-0993

[email protected]

KEYWORDS: United States North America Canada Illinois

INDUSTRY KEYWORDS: Alternative Medicine Health Retail Tobacco Specialty

MEDIA:

Logo